Comparison of anesthetic effects of dexmedetomidine and tramadol, respectively, combined with propofol in percutaneous microwave coagulation therapy for hepatocellular carcinoma

Chu,Chunqin; Yi,Xuanlong; Sun,Jian; Zhang,Xi; Liu,Suli; Zhang,Nannan; Wang,Juntao

doi:10.3892/ol.2019.10717

Comparison of anesthetic effects of dexmedetomidine and tramadol, respectively, combined with propofol in percutaneous microwave coagulation therapy for hepatocellular carcinoma

Authors:
- Chunqin Chu
- Xuanlong Yi
- Jian Sun
- Xi Zhang
- Suli Liu
- Nannan Zhang
- Juntao Wang
View Affiliations

Affiliations: Department of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China, Department of Ultrasound, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China
Published online on: August 6, 2019 https://doi.org/10.3892/ol.2019.10717
Pages: 3599-3604
Copyright: © Chu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Anesthetic effects and safety of dexmedetomidine and tramadol, respectively, combined with propofol in ultrasound‑guided percutaneous microwave coagulation therapy (PMCT) for hepatocellular carcinoma (HCC) were compared. One hundred and seventy‑six patients with HCC, treated by ultrasound‑guided PMCT in The Affiliated Hospital of Qingdao University from January 2014 to December 2016, were retrospectively analyzed and divided into two groups: dexmedetomidine group (anesthetized with dexmedetomidine combined with propofol, n=91) and tramadol group (anesthetized with tramadol combined with propofol, n=85). Changes in heart rate (HR), mean arterial pressure (MAP), and oxygen saturation (SpO2) were recorded before oxygen inhalation (T1), intraoperationally (T2), and at 30 min postoperatively (T3), and the recovery time (recorded from the moment the use of anesthetic drugs stopped), hospital stay, visual analogue scale (VAS) score at 48 h after surgery, as well as the adverse reactions in the perioperative period were compared between the two groups. HR and SpO2 in the dexmedetomidine group at T2 and T3 were significantly lower than those in the tramadol group (P<0.05). HR and SpO2 at T2 were significantly lower than those at T1 and T3, and HR at T3 was lower than that at T1 (P<0.05). MAP in the dexmedetomidine group at T2 was significantly lower than that in the tramadol group (t=3.836, P<0.001). MAP at T2 was significantly lower than those at T1 and T3, and MAP at T3 was lower than that at T1 (P<0.05). The number of patients with shivering in the dexmedetomidine group was significantly higher than that in the tramadol group (P<0.05). Both tramadol and dexmedetomidine, respectively combined with propofol in PMCT for HCC surgery can achieve satisfactory anesthetic effects. However, tramadol combined with propofol is more effective in stabilizing the vital signs with less side‑effects, and is more suitable for PMCT in patients with HCC than dexmedetomidine combined with propofol, which is worth popularizing and applying in clinic.

View Figures

View References

1	Marquardt JU, Andersen JB and Thorgeirsson SS: Functional and genetic deconstruction of the cellular origin in liver cancer. Nat Rev Cancer. 15:653–667. 2015. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Tsai WC, Kung PT, Wang YH, Kuo WY and Li YH: Influence of the time interval from diagnosis to treatment on survival for early-stage liver cancer. PLoS One. 13:e01995322018. View Article : Google Scholar : PubMed/NCBI
4	Li L and Wang H: Heterogeneity of liver cancer and personalized therapy. Cancer Lett. 379:191–197. 2016. View Article : Google Scholar : PubMed/NCBI
5	Kodack DP, Farago AF, Dastur A, Held MA, Dardaei L, Friboulet L, von Flotow F, Damon LJ, Lee D, Parks M, et al: Primary patient-derived cancer cells and their potential for personalized cancer patient care. Cell Rep. 21:3298–3309. 2017. View Article : Google Scholar : PubMed/NCBI
6	Facciorusso A, Di Maso M and Muscatiello N: Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis. Int J Hyperthermia. 32:339–344. 2016. View Article : Google Scholar : PubMed/NCBI
7	Amabile C, Ahmed M, Solbiati L, Meloni MF, Solbiati M, Cassarino S, Tosoratti N, Nissenbaum Y, Ierace T and Goldberg SN: Microwave ablation of primary and secondary liver tumours: Ex vivo, in vivo, and clinical characterisation. Int J Hyperthermia. 33:34–42. 2017. View Article : Google Scholar : PubMed/NCBI
8	Ryan MJ, Willatt J, Majdalany BS, Kielar AZ, Chong S, Ruma JA and Pandya A: Ablation techniques for primary and metastatic liver tumors. World J Hepatol. 8:191–199. 2016. View Article : Google Scholar : PubMed/NCBI
9	Dou JP, Liang P and Yu J: Microwave ablation for liver tumors. Abdom Radiol (NY). 41:650–658. 2016. View Article : Google Scholar : PubMed/NCBI
10	Freeman J and Buggy DJ: Modelling the effects of perioperative interventions on cancer outcome: Lessons from dexmedetomidine. Br J Anaesth. 120:15–17. 2018. View Article : Google Scholar : PubMed/NCBI
11	Miotto K, Cho AK, Khalil MA, Blanco K, Sasaki JD and Rawson R: Trends in tramadol: Pharmacology, metabolism, and misuse. Anesth Analg. 124:44–51. 2017. View Article : Google Scholar : PubMed/NCBI
12	World Health Organization: Expert Committee on Drug Dependence (ECDD) 34th Report. Assessment of tramadol. 2006.
13	Jin Q, Chen X and Zheng S: The security rating on local ablation and interventional therapy for hepatocellular carcinoma (HCC) and the comparison among multiple anesthesia methods. Anal Cell Pathol (Amst) 2019. 29651732019.
14	Petrick JL, Braunlin M, Laversanne M, Valery PC, Bray F and McGlynn KA: International trends in liver cancer incidence, overall and by histologic subtype, 1978–2007. Int J Cancer. 139:1534–1545. 2016. View Article : Google Scholar : PubMed/NCBI
15	Trevisani F, Cantarini MC, Wands JR and Bernardi M: Recent advances in the natural history of hepatocellular carcinoma. Carcinogenesis. 29:1299–1305. 2008. View Article : Google Scholar : PubMed/NCBI
16	Xu LF, Chen YT, Ren Q, Ma HQ, Zhang J, Chen B, Lu PX and Tan ZY: Clinical application of transarterial chemoembolization combining with air-cooled percutaneous microwave coagulation therapy on patients with primary hepatic carcinoma. Chin J Clin Oncol. 34:553–557. 2007.(In Chinese).
17	Potretzke TA, Ziemlewicz TJ, Hinshaw JL, Lubner MG, Wells SA, Brace CL, Agarwal P and Lee FT Jr: Microwave versus radiofrequency ablation treatment for hepatocellular carcinoma: A comparison of efficacy at a single center. J Vasc Interv Radiol. 27:631–638. 2016. View Article : Google Scholar : PubMed/NCBI
18	Jiang X, Gao F, Ma Y, Feng S, Liu X and Zhou H: Percutaneous microwave ablation in the spleen for treatment of hypersplenism in cirrhosis patients. Dig Dis Sci. 61:287–292. 2016. View Article : Google Scholar : PubMed/NCBI
19	Panchgar V, Shetti AN, Sunitha HB, Dhulkhed VK and Nadkarni AV: The effectiveness of intravenous dexmedetomidine on perioperative hemodynamics, analgesic requirement, and side effects profile in patients undergoing laparoscopic surgery under general anesthesia. Anesth Essays Res. 11:72–77. 2017. View Article : Google Scholar : PubMed/NCBI
20	Hoy SM and Keating GM: Dexmedetomidine: A review of its use for sedation in mechanically ventilated patients in an intensive care setting and for procedural sedation. Drugs. 71:1481–1501. 2011. View Article : Google Scholar : PubMed/NCBI
21	Weerink MAS, Struys MMRF, Hannivoort LN, Barends CRM, Absalom AR and Colin P: Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet. 56:893–913. 2017. View Article : Google Scholar : PubMed/NCBI
22	Bhagat N, Yunus M, Karim HM, Hajong R, Bhattacharyya P and Singh M: Dexmedetomidine in attenuation of haemodynamic response and dose sparing effect on opioid and anaesthetic agents in patients undergoing laparoscopic cholecystectomy - A randomized study. J Clin Diagn Res. 10:UC01–UC05. 2016.PubMed/NCBI
23	Falls BA: Opioids and serotonin syndrome: An example with tramadol. In: Neuropathology of Drug Addictions and Substance Misuse - General Processes and Mechanisms, Prescription Medications, Caffeine and Areca, Polydrug Misuse. Emerging Addictions and Non-Drug Addictions. Preedy VR: 3. Elsevier Inc., Academic Press; London: pp. 443–448. 2016
24	Faria J, Barbosa J, Queirós O, Moreira R, Carvalho F and Dinis-Oliveira RJ: Comparative study of the neurotoxicological effects of tramadol and tapentadol in SH-SY5Y cells. Toxicology. 359-360:1–10. 2016. View Article : Google Scholar : PubMed/NCBI
25	Bedirli N, Akçabay M and Emik U: Tramadol vs dexmedetomidine for emergence agitation control in pediatric patients undergoing adenotonsillectomy with sevoflurane anesthesia: Prospective randomized controlled clinical study. BMC Anesthesiol. 17:412017. View Article : Google Scholar : PubMed/NCBI
26	Sahi S, Singh MR and Katyal S: Comparative efficacy of intra-venous dexmedetomidine, clonidine, and tramadol in postanesthesia shivering. J Anaesthesiol Clin Pharmacol. 32:240–244. 2016. View Article : Google Scholar : PubMed/NCBI